Determination of Regulatory Review Period for Purposes of Patent Extension; MIFEPREX; Extension of Comment Period

Короткий зміст

The Food and Drug Administration (FDA) is extending to April 26, 2002, the comment period for the regulatory review period determination for MIFEPREX, published in the Federal Register of January 25, 2002 (67 FR 3724). The agency is taking this action in response to a request for an extension.